Search Results

You are looking at 171 - 180 of 2,860 items for :

  • Refine by Access: All x
Clear All
Full access

BIO24-031: Hierarchical Multimodal Learning on Pan-Squamous Cell Carcinomas for Improved Survival Outcomes

Asim Waqas, Aakash Tripathi, Ashwin Mukund, Paul Stewart, Mia Naeini, and Ghulam Rasool

clinical outcomes. Our framework (1) generates embeddings from multi-resolution datasets, (2) learns and improves relational embeddings at various stages of data hierarchy using GNNs, (3) fuses the learned embeddings into a unified graph representation, and

Full access

CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer

Kristen Kelley, Audrey York, Benjamin Haaland, Xuechen Wang, Shiven Patel, Adriana Coletta, and Christos Vaklavas

chemotherapy may be superior. The objective of this study is to assess the relationship between dose timing and outcomes in breast cancer patients. Methods : 153 patients who had neoadjuvant chemotherapy in 2014-2020 were included. Chemotherapy administration

Full access

Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?

Alejandro Garcia-Horton and Jeffrey H. Lipton

possible without widespread treatment and availability of TKIs, resulting in disease control and molecular response. Treatment-free remission (TFR) has emerged as a new goal for many patients with CML as a distinct outcome other than overall survival (OS

Full access

Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner

, 31% (n=68) of patients received no treatment ( Table 3 ). From 1995 to 1998, most patients did not receive any treatment. Liver-directed therapy became more prevalent from 2007 to 2010 ( Figure 2 ). Survival Outcomes No statistically

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

-analysis calculations. Data Extraction and Outcomes Information recorded from each eligible trial included author names; journal; year of publication; number of centers involved; number of patients randomly assigned and analyzed per arm; years of patient

Full access

Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer

Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill

supporting evidence that it improves outcomes. 1 , 2 Yet imaging, either in response to patient symptoms or for surveillance, is common in the management of patients with ovarian cancer in first remission among providers at academic medical centers. 3 In a

Full access

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

RCTs. It should be mentioned that PS was not found in 25% of patients. Therefore, real-world data are a valuable addition to trial results because they deepen the understanding of the outcome of therapies in patients encountered on a day-to-day basis

Full access

Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis

natural history, management, and outcome. Professional societies have published guidelines for the diagnosis, management, and treatment of HCV infection, 9 specific sections of which address immunocompromised patients, such as HIV coinfected patients and

Full access

Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma

Bishal Gyawali

or none a decade ago, but the billion dollar question is whether outcomes for patients with advanced liver cancer have improved as a result. Some of the statistics are concerning. Although it is too early to observe the effect of new drug approvals

Full access

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors

Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

: TCS completed a questionnaire regarding health outcomes, lifestyle behaviors, and current prescription medications (including antihypertensive, diabetic, and lipid-lowering medications). Demographic information included age at cancer diagnosis and